NCT06946485

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

A Clinical Study of the Safety and Efficacy of Universal Anti-CD70 CAR-T (CHT101) for the Treatment of Relapsed and Refractory Systemic Lupus Erythematosus

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.

Detailed description

This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.

Conditions

• Systemic Lupus Erythematosus (SLE)

Interventions

Type	Name	Description
BIOLOGICAL	Universal anti-CD70 CAR-T (CHT101)	Universal anti-CD70 CAR-T (CHT101) cell therpy

Timeline

• Start date: 2025-04-01
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2025-04-27
• Last updated: 2026-04-07

Locations

1 site across 1 country: China